Back to Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 2

Developments in the management of autosomal dominant polycystic kidney disease

Authors Masoumi A, Reed-Gitomer B, Kelleher C, Bekheirnia MR, Schrier RW

Published 11 April 2008 Volume 2008:4(2) Pages 393—407


Amirali Masoumi, Berenice Reed-Gitomer, Catherine Kelleher, Mir Reza Bekheirnia, Robert W Schrier

Department of Medicine, Health Sciences Center, University of Colorado School of Medicine, Denver, CO 80262, USA

Abstract: Autosomal dominant polycystic kidney disease (ADPKD) is the most frequent life- threatening, hereditary disease. ADPKD is more common than sickle cell anemia, cystic fibrosis, muscular dystrophy, hemophilia, Down’s syndrome, and Huntington’s disease combined. ADPKD is a multisystemic disorder characterized by the progressive development of renal cysts and marked renal enlargement. Structural and functional renal deterioration occurs in ADPKD patients and is the fourth leading cause of end-stage renal disease (ESRD) in adults. Aside from the renal manifestations, extrarenal structural abnormalities, such as liver cysts, cardiovascular abnormalities, and intracranial aneurysms may lead to morbidity and mortality. Recent studies have identified prognostic factors for progressive renal impairment including gender, race, age, proteinuria, hematuria, hypertension and increased left ventricular mass index (LVMI). Early diagnosis and better understanding of the pathophysiology of the disease provides the opportunity to aggressivly treat hypertension with renin-angiotensin-aldosterone system inhibitors and thereby potentially reduce LVMI, prevent cardiovascular morbidity and mortality and slow progression of the renal disease.

Keywords: hypertension, liver cysts, renal pain, left ventricular hypertrophy, cerebral aneurysms

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]